Apr 16 |
GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patent
|
Apr 8 |
GRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International Conference
|
Apr 1 |
GRI Bio reports FY results
|
Apr 1 |
GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update
|
Mar 28 |
GRI Bio to Present at the MedInvest Biotech & Pharma Investor Conference
|
Mar 14 |
GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulators
|
Mar 4 |
GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom
|
Feb 23 |
Top 4 Health Care Stocks That Are Preparing To Pump This Month
|
Feb 22 |
Why NVIDIA Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
|
Feb 2 |
S&P 500 Gains Over 1%; Amazon Earnings Top Expectations
|